The study found a key immune system target, called the NLRP3 inflammasome, lights up in Parkinson’s patients, with signals found in the brain and even in the blood.
“MCC950, given orally once a day, blocked NLRP3 activation in the brain and prevented the loss of brain cells, resulting in markedly improved motor function.”
The drug is now being commercialised by a company called Inflazome. Phase 1 clinical trials with healthy volunteers will start in 2019, with phase 2 trials in Parkinson’s patients scheduled for 2020
“We are indebted to The Michael J. Fox and Shake It Up Australia Foundations for supporting this work".
Prof. Matt Cooper, Co-founder and CEO of Inflazome
“Inflazome has validated a promising new target for Parkinson’s therapeutics and translated that finding into a potential drug to treat Parkinson’s disease".
Kuldip Dave, PhD, Director of Research Programs at The Michael J. Fox Foundation
“Shake It Up is proud and excited to be a part of the collaboration’s funding team, allowing highly talented researchers an opportunity to create world leading breakthroughs that have the opportunity to be a game changer for people with Parkinson’s,”
Clyde Campbell, Founder and CEO of the Shake It Up Foundation.
|
